Clinical observation of lobaplatin versus cisplatin combined with etoposide in the treatment of extensive-stage small cell lung cancer
WANG Jun
WANG Jianzhong
ZHANG Changchun
YANG Yong
LUO Yi
Abstract：Objective To investigate the therapeutic effect, long term survival and side effects on small cell lung cancer (SCLC) patients treated with lobaplatin combined with etoposide. Methods Eighty?five patients with extensive?stage SCLC were retro?spectively analyzed. Among these patients, 85 patients were assigned to EL group(etoposide 80 mg/ m2 , d1?d5+lobaplatin 30 mg/ m2 , d1; 21 days as a cycle; n= 42) and EP group(etoposide 80 mg/ m2 , d1?d5+cisplatin 25 mg/ m2 , d1?d3; 21 days as a cycle; n= 43). Efficacy and toxicities were evaluated after 2 or more cycles. Results The overall response rate were 59?? 5% and 53?? 5%, and the dis?ease control rate were 80?? 9% and 76?? 7% in EL group and EP group without significant difference(P>0?? 05). The median progression free survival of EL group was 6?? 5 months, higher than 4?? 5 months in EP group with significant difference(P<0?? 05). There were higher incidences of thrombocytopenia but lower incidence of nausea and vomiting and liver and kidney impairment in EL group versus EP group(P<0?? 05). Conclusion Compared with the EP regimen, the EL regimen can prolong the median progression survival and re?duce gastrointestinal toxicity.
Keywords：Small cell lung cancerChemotherapyEtoposideCisplatinLobapaltin
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 168-170 )